前列腺癌筛查MRI国际共识:PRISM建议
基于系统综述与Meta分析纳入6项研究、1919例参与者,其中1426例接受前瞻性筛查MRI。采用RAND/UCLA适宜性方法形成共识,21名专家对323条声明中235条达成一致。PRISM为前列腺癌筛查MRI的采集、解读与报告提供标准化指导。
要点
- 筛查MRI推荐用于预期寿命大于10年、50-70岁男性,黑人男性可从45岁开始
- 推荐仅含T2WI和DWI的非增强MRI,采集时间最长不超过15分钟
- 报告采用分期门控两步法,仅在轴位T2WI和高b值DWI发现可疑病灶后才显示所有序列
核心结论
- PRISM共识为前列腺癌筛查MRI提供标准化专家指导,涵盖简化非增强方案、筛查间隔、分期门控报告及质量保证标准
- 筛查MRI推荐在PSA检测后进行,但专家组未就最佳PSA阈值达成共识
研究设计与样本
- 国际共识建议,基于系统综述与Meta分析,检索PubMed、CENTRAL、Scopus、Web of Science和ClinicalTrials.gov,时间为2024年9月
- 纳入6项研究共1919例参与者,其中1426例接受前瞻性筛查MRI,多数研究采用3.0T非增强MRI
- 采用RAND/UCLA适宜性方法进行共识形成,专家组共21人,包括8名泌尿外科医生、11名放射科医生和2名病理科医生,来自6个国家
关键影像表现/征象
- 多数筛查研究采用3.0T非增强MRI方案
- 分期门控两步法中,第一步仅在轴位T2WI和高b值DWI上识别一致性局灶性病变,第二步才显示所有序列
诊断标准与关键数值
- 合并活检推荐率为19.2%(95%CI,11.7-26.7)
- GG2及以上前列腺癌检出率为6.0%(95%CI,3.1-9.0),GG1癌检出率为1.4%(95%CI,0.7-2.2)
- GG2及以上癌症的阳性预测值为36.3%(95%CI,21.1-51.4)
- 筛查MRI推荐用于预期寿命大于10年、年龄50-70岁男性,黑人男性从45岁开始
- 323条共识声明中235条(72.8%)达成一致
临床应用与阅片要点
- 仅含T2WI和DWI的非增强MRI被认为是合适的,最大可接受采集时间为15分钟
- 重复筛查应根据患者特征进行风险分层安排
- 筛查MRI仅应在认证中心进行,放射科医生须满足最低报告要求和质量标准
- 筛查MRI应在PSA检测后进行,但PSA最佳阈值尚无共识
局限性
- 纳入的研究数量仅6项,总样本量1919例中仅1426例接受了前瞻性筛查MRI
- 专家组未就最佳PSA阈值达成共识
- 323条共识声明中仅72.8%达成一致,其余未达成共识
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
IMPORTANCE: Magnetic resonance imaging (MRI) is routinely used in prostate cancer diagnosis, but there is uncertainty about its optimal use in population-level screening.
OBJECTIVE: To provide consensus recommendations on the acquisition, interpretation, and reporting of prostate MRI for cancer screening.
EVIDENCE REVIEW: A systematic review and meta-analysis of randomized clinical trials and prospective cohort studies evaluating MRI for prostate cancer screening was conducted for these international consensus recommendations. A search of PubMed, CENTRAL, Scopus, Web of Science, and ClinicalTrials.gov, citation searching, and consultation with experts was performed in September 2024. Studies performing upfront MRI for the purpose of prostate cancer screening were included.
FINDINGS: A total of 6 studies were identified and included 1919 participants, of whom 1426 underwent upfront screening MRI. Most studies used 3.0-T non-contrast-enhanced MRI. The pooled biopsy recommendation rate was 19.2% (95% CI, 11.7-26.7), with grade group (GG) 2 or higher prostate cancer detection of 6.0% (95% CI, 3.1-9.0) and GG1 cancer detection of 1.4% (95% CI, 0.7-2.2). The positive predictive value for GG2 or higher cancer was 36.3% (95% CI, 21.1-51.4). Findings informed a RAND/UCLA Appropriateness Method consensus exercise used to produce the Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM) recommendations. A total of 21 experts (8 urologists, 11 radiologists, and 2 pathologists from 6 countries) were included on the panel. Among 323 consensus statements, 235 (72.8%) reached agreement. If MRI is used in screening, it is recommended for men with an estimated life expectancy greater than 10 years and aged 50 to 70 years or from age 45 years in Black men. Screening MRI should be performed in men after a prostate-specific antigen (PSA) test, but there was no consensus on the optimal PSA threshold. Non-contrast-enhanced MRI with only T2-weighted and diffusion-weighted imaging was considered appropriate, with a maximum acceptable acquisition time of 15 minutes. The stage-gated (2-step) approach to reporting, where all MRI sequences are only revealed (second step) if a concordant focal lesion is identified on axial T2-weighted and high b-value diffusion imaging (first step), was recommended. Repeat screening should be risk stratified according to patient characteristics. Screening MRI should only be performed in accredited centers with radiologists meeting minimum reporting requirements and quality standards.
CONCLUSIONS AND RELEVANCE: The PRISM consensus recommendations provide standardized expert guidance on the use of MRI in prostate cancer screening trials and future screening programs, including abbreviated non-contrast-enhanced MRI protocols, recommended screening intervals, stage-gated reporting, and quality assurance standards.
引用
- Mayor, Light, Gopalakrishnan, et al. Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations. JAMA Oncol. 2026. PMID: 42275039. doi:10.1001/jamaoncol.2026.1711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。